Trial Profile

Phase I/II Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 08 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Ivuxolimab (Primary) ; Utomilumab (Primary)
Indications Colon cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Pancreatic cancer; Prostate cancer; Solid tumours
Focus Adverse reactions; Biomarker; Pharmacodynamics

10 Mar 2025 Results (n=31) assessing safety and efficacy of avelumab in combination with ivuxolimab, with or without utomilumab, and radiation therapy in a subgroup analysis of patients with advanced gastrointestinal (GI) tumors (pancreatic, colon, gastric, and hepatocellular) published in the Oncologist.
19 Sep 2024 Planned End Date changed from 30 Sep 2024 to 30 Sep 2025.
19 Sep 2024 Planned primary completion date changed from 30 Sep 2024 to 30 Sep 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com